Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temelimab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ANGEL-MS
  • Sponsors GeNeuro

    • Most Recent Events

    • 03 Apr 2022 This trial has been completed in Hungary and Italy (End Date: 14 Nov 2018), according to European Clinical Trials Database record.
    • 01 Mar 2022 Results from randomized phase 2b and extension study published in the Multiple Sclerosis Journal
    • 16 Sep 2019 According to a GeNeuro media release, results of this extension study were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) Congress (Stockholm, Sweden).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top